Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Bariatric and metabolic surgery
7 evidence topics · 6 sources
AASLD 2023 practice guidance on bariatric surgery
“Bariatric surgery should be considered as a therapeutic option in patients who meet criteria for metabolic weight loss surgery, as it effectively resolves NAFLD or NASH in the majority of patients without cirrhosis and reduces mortality from CVD and malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The type, safety, and efficacy of bariatric surgery in patients with well-compensated NASH cirrhosis is not established and requires a careful benefit–risk assessment by a multidisciplinary team of experts that includes a hepatologist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Failure to achieve substantial weight loss following bariatric surgery is associated with persistent NASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EASL-EASD-EASO recommendation on bariatric surgery in non-cirrhotic MASLD
ADA Standards of Care 2026: metabolic surgery in adults with type 2 diabetes and MASH
“Consider metabolic surgery in appropriate candidates as an option to treat MASH in adults with type 2 diabetes and obesity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses report that 70–80% of people have improvement in hepatic steatosis, 50–75% of people have improvement in inflammation and hepatocyte ballooning (necrosis), and 30–40% of people have improvement in fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that currently metabolic surgery is not indicated solely for treatment of MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BRAVES randomized trial: Roux-en-Y gastric bypass or sleeve gastrectomy vs lifestyle modification plus best medical care, 1-year histology
“We did a multicentre, open-label, randomised trial at three major hospitals in Rome, Italy. We included participants aged 25-70 years with obesity (BMI 30-55 kg/m2), with or without type 2 diabetes, with histologically confirmed NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint of the study was histological resolution of NASH without worsening of fibrosis at 1-year follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the intention-to-treat analysis, the percentage of participants who met the primary endpoint was significantly higher in the Roux-en-Y gastric bypass group (54 [56%]) and sleeve gastrectomy group (55 [57%]) compared with lifestyle modification (15 [16%]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Severe adverse events occurred in ten (6%) participants who had bariatric-metabolic surgery, but these participants did not require re-operations and severe adverse events were resolved with medical or endoscopic management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
BRAVES randomized trial: fibrosis improvement at 1 year and fibrosis stage of participants
Prospective cohort of 180 adults with severe obesity and biopsy-proven NASH: histology 5 years after bariatric surgery
“We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SPLENDOR cohort: major adverse liver outcomes and cardiovascular events at 10 years after bariatric surgery in fibrotic NASH without cirrhosis
“In this retrospective cohort study of 1158 patients (including 650 patients who underwent bariatric surgery and 508 patients in the nonsurgical control group) with biopsy-proven fibrotic nonalcoholic steatohepatitis without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes (adjusted absolute 10-year risk difference of 12.4%) and major adverse cardiovascular events (adjusted absolute 10-year risk difference of 13.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients analyzed with overlap weighting methods, the cumulative incidence of major adverse liver outcomes at 10 years was 2.3% (95% CI, 0%-4.6%) in the bariatric surgery group and 9.6% (95% CI, 6.1%-12.9%) in the nonsurgical group (adjusted absolute risk difference, 12.4% [95% CI, 5.7%-19.7%]; adjusted hazard ratio, 0.12 [95% CI, 0.02-0.63]; P = .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the first year after bariatric surgery, 4 patients (0.6%) died from surgical complications, including gastrointestinal leak (n = 2) and respiratory failure (n = 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote